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Hormonal and nutrient regulation of hepatic gluconeogenesis mainly occurs through modulation of the transcriptional co-
activator PGC-1a. The identity of endogenous proteins and their enzymatic activities that regulate the functions and form
part of PGC-1a complex are unknown. Here, we show that PGC-1a is in a multiprotein complex containing the acetyltrans-
ferase GCN5. PGC-1a is directly acetylated byGCN5 resulting in a transcriptionally inactive protein that relocalizes frompro-
moter regions to nuclear foci. Adenoviral-mediated expression of GCN5 in cultured hepatocytes and in mouse liver largely
represses activation of gluconeogenic enzymes and decreases hepatic glucose production. Thus, we have identified the
endogenous PGC-1a protein complex and provided the molecular mechanism by which PGC-1a acetylation by GCN5 turns
off the transcriptional and biological function of this metabolic coactivator. GCN5 might be a pharmacological target to
regulate the activity of PGC-1a, providing a potential treatment for metabolic disorders in which hepatic glucose output
is dysregulated.Introduction
Maintenance of glucose homeostasis in mammals is accom-
plished through a tight regulation of glucose uptake by periph-
eral tissues and by production of glucose mainly in the liver.
These metabolic processes constantly fluctuate in the normal
physiology of feeding/fasting. After a meal, circulating blood in-
sulin levels increase thereby blocking glucose production by the
liver and inducing glucose uptake in tissues such as skeletal
muscle and adipose. In contrast, in the fasted state glucagon
signals to increase hepatic glucose output to maintain blood
glucose levels within a narrow range, as neuronal and red blood
cells utilize glucose as a main energetic fuel. In pathological
states such as diabetes, insulin signaling is impaired, resulting
in dysregulation of both glucose uptake in peripheral tissues
and hepatic glucose output (Flier, 2004; Saltiel, 2001; Shulman,
2000). Therefore, efforts to gain insight into molecular mech-
anisms that control these metabolic processes are crucial to
develop new therapeutic strategies.
A major contributor of fasting hyperglycemia in diabetes is an
increased production of glucose by the liver. This metabolic pro-
cess is largely controlled at the transcriptional level through
hormonal and nutrient signals that activate key enzymes in the
gluconeogenic pathway such as G6Pase and PEPCK. Several
transcriptional components have been identified that control
gene expression of these enzymes including transcription
factors CREB, FOXO1, HNF4a, GR and C/EBPs (Herzig et al.,
2001; Imai et al., 1990; Nakae et al., 2001; Rhee et al., 2003;
Yoon et al., 2001). In this transcriptional regulatory network,
the metabolic coactivator PGC-1a has been shown to modulate
the gluconeogenic pathway in fasted and diabetic states
through interaction with several of these transcription factors
(Yoon et al., 2001). The coactivator PGC-1a also regulatesCELL METABOLISM 3, 429–438, JUNE 2006 ª2006 ELSEVIER INC. Dgenetic programs associated with oxidative metabolism and
the nutritional food deprivation response (Knutti and Kralli,
2001; Lin et al., 2005). Notably, PGC-1a function is dysregulated
in diabetic human muscle (Mootha et al., 2003) as well as in the
liver of diabetic mice (Yoon et al., 2001). Specific knock-down of
PGC-1a in the liver of diabetic mice is sufficient to normalize
blood glucose levels (Koo et al., 2004). Furthermore, liver spe-
cific null mice present abnormal hepatic production of glucose
and decreased blood glucose levels (Handschin et al., 2005).
Although in recent years signaling pathways and transcription
factors that dictate the biological function of PGC-1a have been
identified, the biochemical machinery that controls PGC-1a
transcriptional function and how it is regulated remains largely
unknown. Initial studies found that histone acetyltransferases
p300 and SRC-1 bind to the N-terminal activation domain
increasing the transcriptional activity after docking to transcrip-
tion factors (Puigserver et al., 1999). Roeder’s group have iden-
tified the TRAP/Mediator complex that binds to the C terminus
of PGC-1a through direct interaction with the TRAP220 subunit
and cooperates with p300 to augment transcriptional activity
(Wallberg et al., 2003). However, the endogenous PGC-1a
complex and the associated enzymatic activities that are being
recruited to PGC-1a to modulate gene expression have re-
mained elusive.
Hormonal signaling through glucagon and glucocorticoids in-
creases PGC-1a gene expression via glucocorticoid receptor
and the CREB/TORC pathway (Herzig et al., 2001; Koo et al.,
2005; Yoon et al., 2001). In contrast, insulin decreases PGC-1a
function through AKT-mediated phosphorylation of FOXO1
(Puigserver et al., 2003). In parallel to this hormonal regulation,
we have recently found that a nutrient pathway also modulates
the gluconeogenic activity of PGC-1a in the fasted state through
the NAD+-dependent deacetylase SIRT1 (Rodgers et al., 2005).OI 10.1016/j.cmet.2006.04.013 429
A R T I C L ESIRT1 deacetylates PGC-1a in the fasted liver to control secre-
tion of glucose. This might provide ametabolic adaptation in ca-
loric restriction and how it could influence life span-dependent
biological processes. A key question remaining from these
studies was what is the endogenous acetyltransferase that, by
functioning in opposite direction of SIRT1 deacetylase, would
negatively impact PGC-1a function.
Taken together, our studies have identified the endogenous
PGC-1a complex that contains at least two different protein
complexes, GCN5 and TIP60 acetyltransferases. Moreover,
we have found that GCN5 is the specific acetyltransferase for
PGC-1a. Consistent with the activation effect of SIRT1 on
PGC-1a through deacetylation, we show here that acetylation
of PGC-1a by GCN5 is critical to block its activity through local-
ization to nuclear inactive transcriptional domains. Finally,
GCN5 represses PGC-1a ability to induce gluconeogenic gene
expression and hepatic glucose secretion in cultured hepato-
cytes and in mice.
Results
Identification of GCN5 and TIP60 acetyltransferase
complexes as part of the PGC-1a protein complex
We have previously reported that SIRT1 is a specific deacety-
lase of PGC-1a and is part of a nutrient signaling pathway in
the food deprivation response (Rodgers et al., 2005). In order
to identify the endogenous PGC-1a acetyltransferase, we puri-
fied PGC-1a protein holo-complexes from cultured hepatocytes
as described in Experimental Procedures. Basically, nuclear ex-
tracts from Fao hepatocytes expressing a dually tagged Flag-
HA-PGC-1a (FH-PGC-1a) were fractionated by FPLC through
a gel filtration column. Fractions containing FH-PGC-1a were
subjected to immunoaffinity chromatography. Polypeptides
that copurified with PGC-1a were analyzed and sequenced by
LC-MS/MS. A complete list of proteins that associated specifi-
cally with PGC-1a is provided in Figure S1 available in the Sup-
plemental Data available with this article online. We purified two
proteins with histone acetyltransferase (HAT) activity, GCN5 and
TIP60. Both proteins have been shown to form large protein
complexes (Ikura et al., 2000; Martinez et al., 2001), and most
of their respective subunits were also present in the PGC-1a pu-
rified material (Figure 1A). We confirmed the specificity of some
of these interactions by coimmunoprecipitation and Western
blot analysis of different proteins from the GCN5 complex
(GCN5, SAP130, TAFII31, and PAF65b) and the TIP60 complex
(RuvBL1) as well as KAP-1 (Figure 1B). To test for the presence
of distinct PGC-1a complexes, we performed glycerol gradient
ultracentrifugation using the purified PGC-1a fraction after im-
munoaffinity chromatography. GCN5 and TAFII31 (GCN5 com-
plex) separated in different fractions as compared to RuvBL1
(TIP60 complex) (Figure 1C), suggesting that PGC-1a is present
in at least two different protein complexes associatedwith either
GCN5 or TIP60 complexes. We next determined whether the in-
teraction between GCN5 and TIP60 with PGC-1a was direct by
performing in vitro binding assays with fragments of PGC-1a
fused to GST and GCN5 or TIP60. GCN5 and TIP60 strongly
interacted with the N-terminal activation domain of PGC-1a,
a region that has been shown to interact with other acetyltrans-
ferases such as CBP/p300 and SRC-1 (Puigserver et al., 1999)
(Figure 1D, top and middle panels). In the case of GCN5, the
main interaction domain with PGC-1a was the bromodomain430(Figure 1D, bottom panel), a region known to mediate inter-
actions with proteins involved in regulation of transcription
(Hassan et al., 2002). As expected, purified PGC-1a complexes
contained strong HAT activity, mainly toward histone 3 and to
a lesser extent histone 4 (Figure 1E), consistent with the pres-
ence of GCN5 and TIP60 in the PGC-1a complexes. Taken
together, these results indicate that PGC-1a is part of large
endogenous protein complexes in hepatic cells containing the
GCN5 and TIP60 acetyltransferases subcomplexes.
GCN5 is the specific acetyltransferase for PGC-1a
We have previously shown that PGC-1a is highly acetylated at
multiple lysines after treatment with the SIRT1 inhibitor nicotin-
amide (Rodgers et al., 2005), indicating that there must exist
a protein acetyltransferase that directly acetylates PGC-1a. As
both GCN5 and TIP60 were the only protein acetyltransferases
identified in the complex, either could potentially acetylate
PGC-1a. As shown in Figure 2A, expression of GCN5 (and its
close homolog PCAF) induced acetylation of PGC-1a in
HEK293 cells. In contrast, other acetyltransferases such as
p300, SRC1—both previously shown to interact with PGC-1a
(Puigserver et al., 1999; Wallberg et al., 2003)—as well as
TIP60 did not induce acetylation of PGC-1a, while p300 did
acetylate p53 (Figure 2A, bottom panel). Adenoviral-mediated
expression of GCN5 in hepatic cells also acetylated PGC-1a
(Figure S2). To determine whether PGC-1a acetylation was
dependent on GCN5 acetyltransferase activity, we used a previ-
ously described catalytically inactive GCN5 mutant (Y621A/
P622A) (Liu et al., 2003). As shown in Figure 2B, this GCN5 mu-
tant (GCN5m) was unable to acetylate PGC-1a. To determine
whether endogenous GCN5 was required for PGC-1a acetyla-
tion, we used a GCN5 RNAi construct to reduce GCN5 protein
levels. As shown in Figure 2C, cells expressing GCN5 RNAi
showed a decreased PGC-1a acetylation in response to nicotin-
amide. Furthermore, in vitro acetylation experiments using
recombinant GCN5 and a fragment of PGC-1a (1–400 aa)
showed that GCN5 directly acetylates PGC-1a (Figure 2D).
Together, these data indicate that GCN5 is an endogenous
acetyltransferase of PGC-1a.
GCN5 acetyltransferase is a repressor of PGC-1a
transcriptional activity
To analyze the functional consequences of the interaction and
acetylation of PGC-1a by GCN5, we performed transcriptional
luciferase reporter assays usingGAL4-DBD- PGC-1a. As shown
in Figure 3A, GCN5 repressed the transcriptional activity of
GAL4-DBD- PGC-1a by 35-fold. Conversely, p300, which did
not acetylate PGC-1a (see Figure 2A), strongly activated GAL4-
DBD- PGC-1a (Figure 3A and Puigserver et al., 1999). As a neg-
ative control, we showed that GCN5 did not repress but slightly
activated GAL4-DBD-VP16 (Figure 3B). These results indicate
that GCN5 repressed PGC-1a intrinsic transcriptional activity.
To further determine whether GCN5 also repressed coactivation
function on a transcription factor context, we used the hormone
nuclear receptor HNF4a. As shown previously (Yoon et al.,
2001), PGC-1a strongly activated HNF4a -dependent transcrip-
tional activity. However, expression of GCN5 repressed this
activity by 6-fold (Figure 3C). Similar results were also obtained
using PEPCK promoter (Figure 3D), a previously described en-
dogenous targetofPGC-1a (Puigserver et al., 2003). Importantly,
this GCN5 repression was dependent on its acetyltransferaseCELL METABOLISM : JUNE 2006
Regulation of glucose metabolism by GCN5Figure 1. Physical association of PGC-1a with GCN5 and TIP60 acetyltransferase complexes
A)GCN5 and TIP60 complex subunits are associated with PGC-1a. Proteins identified by LC-MS/MS in the purified PGC-1a complexes belonging to either GCN5 or TIP60
complexes are listed.
B) Coimmunoprecipitation of PGC-1a with proteins identified in PGC-1a complexes. PGC-1a complexes were subjected to Western blot using the indicated antibodies.
C)Glycerol gradient analysis of PGC-1a complexes. PGC-1a complexeswere separated on a glycerol gradient by ultracentrifugation and fractions were analyzed byWest-
ern blot using the indicated antibodies.
D) PGC-1a physically interacts with GCN5 and TIP60. GST- PGC-1a fusion proteins bound to sepharose beads were incubated with 35S-methionine in vitro translated
GCN5 or TIP60 proteins. After the binding reaction, precipitates were separated by SDS-PAGE and analyzed by autoradiography.
E) PGC-1a complexes contain histone acetyltransferase activity. Purified PGC-1a complexeswere used in an in vitro histone acetylation reaction. Histones were separated
by SDS-PAGE and analyzed by Coomassie staining and autoradiography.activity, as the catalytically inactive GCN5 mutant did not sig-
nificantly affect PGC-1a activity in luciferase assays (Figures
3C and 3D). Moreover, consistent with the inhibitory effect
of GCN5 overexpression on PGC-1a transcriptional activity,
decreasing GCN5 levels using GCN5 RNAi increased HNF4a
activation by PGC-1a (Figure 3E). Taken together, these results
indicate that GCN5 functions as a transcriptional repressor of
PGC-1a and that this repression depends on its acetyltransfer-
ase activity.
GCN5 acetyltransferase induces translocation
of PGC-1a to subnuclear domains
It has been previously shown that PGC-1a activates gluco-
neogenic gene expression by recruitment to the regulatoryCELL METABOLISM : JUNE 2006promoter regions through interaction with transcription factors
(Puigserver et al., 2003). To determine the mechanism of
GCN5 transcriptional repression, we performed ChIP experi-
ments to analyze whether GCN5 could relocalize PGC-1a from
endogenous gluconeogenic PEPCK and G6Pase promoters.
As shown in Figure 4A, PGC-1a occupies these promoters
and expression of GCN5 decreased its binding. This suggests
that repression of gene transcription by GCN5-mediated acety-
lation of PGC-1a is through diminished binding to the active pro-
moter sequence. We then examined whether PGC-1a nuclear
localization was affected by performing immunofluorescence
microscopy analysis in hepatocytes. As shown in Figure 4B,
PGC-1a localized uniformly in the nucleus. However, when
GCN5 was expressed both PGC-1a and GCN5 colocalized to431
A R T I C L EFigure 2. Acetylation of PGC-1a through GCN5 acetyltransferase activity
A) GCN5 induces PGC-1a acetylation. HEK293 cells were transfected with the indicated plasmids. FH- PGC-1a (top panel) or Flag-p53 (midle panel) were immunopre-
cipitated and acetylation levels were analyzed by Western blot.
B) A catalytically inactive GCN5 mutant does not acetylate PGC-1a. HEK293 cells were transfected with the indicated plasmids and PGC-1a acetylation levels were an-
alyzed by Western blot.
C) GCN5 RNAi decreases PGC-1a acetylation. HEK293 cells were transfected with the indicated plasmids and treated with 10 mM nicotinamide for 16 hr. PGC-1a acet-
ylation levels were analyzed by Western blot.
D) In vitro acetylation of PGC-1a by GCN5. Recombinant GST- PGC-1a (1–400 aa) and GST-GCN5 (352–837 aa) proteins were used in an in vitro acetylation assay. Values
represent means 6 SEM of three independent experiments performed in duplicate; *p < 0.0001, versus PGC-1a.distinctive nuclear punctuate pattern (Figure 4B, middle panel).
This new nuclear foci distribution of PGC-1a depended on
GCN5 acetyltransferase activity as GCN5m did not promote
this nuclear distribution (Figure 4B, bottom panel). Moreover,
PGC-1a localization to these nuclear foci required the C-termi-
nal domain of PGC-1a, as GCN5 did not relocalize a PGC-1a
deletion (1–570 aa) (Figure 4C). Interestingly, it was previously
reported that in certain cell types PGC-1a is localized to nuclear
speckles with splicing factors (Monsalve et al., 2000). How-
ever, after extensive microscopic analysis we found that
PGC-1a -GCN5 containing nuclear punctuate structures did
not colocalize with nuclear speckles containing splicing factors
or snRNPs (SC35, Sm, U1snRNP70K, and U2-B0 0) (Lamond and
Spector, 2003), PML bodies (SP100) (Hodges et al., 1998), nu-
cleolar organizing regions (fibrillarin) (Bubulya et al., 2004), poly-
comb bodies (Pc2) (Kagey et al., 2003), or matrix-associated
deacetylase bodies (SMRT) (Downes et al., 2000) (Figure S3).
Instead,we found that PGC-1a largely colocalizedwith a nuclear
corepressor for hormone nuclear receptors, RIP140 (Christian
et al., 2004; Zilliacus et al., 2001) (Figure 4D), suggesting that
these nuclear structures represent spatial sites to which regula-
tors of gene transcription are recruited. An interesting possibility
is that these nuclear foci could represent structures that contain432repressive chromatin similar to theDrosophila insulators (Capel-
son and Corces, 2004).
GCN5 acetyltransferase blocks PGC-1a-induced
gluconeogenic gene expression and hepatic
glucose secretion
We have recently shown that deacetylation of PGC-1a through
SIRT1 deacetylase is part of a nutrient pathway in response to
food deprivation and is required to activate hepatic gluco-
neogenic PGC-1a target genes such as G6Pase and PEPCK
(Rodgers et al., 2005). The fact that GCN5 acetylates and
represses PGC-1a prompted us to investigate the effects of
GCN5 on PGC-1a -dependent gluconeogenic gene expression.
Hepatocytes were infected with adenoviruses expressing
PGC-1a and GCN5 and mRNA levels for G6Pase and PEPCK
were analyzed. Consistent with both the effects of SIRT1 on
PGC-1a (Rodgers et al., 2005) as well as the transcriptional as-
says (see Figure 3), expression of GCN5 largely decreased
PGC-1a -induction of gluconeogenic genes (Figure 5A). Inter-
estingly, the repression of PGC-1a by GCN5 also affected the
mitochondrial genes cytochrome c and b-ATP-synthase
(Figure 5A). These results indicate that GCN5 acts as a general
repressor of PGC-1a. Notably, these effects were mediated to aCELL METABOLISM : JUNE 2006
Regulation of glucose metabolism by GCN5Figure 3. Repression of PGC-1a transcriptional activity through GCN5 acetyltransferase activity
HEK293 cells were transfected with the indicated plasmids together with a 5xUAS reporter luciferase construct (A and B), HNF4a and gAF1 reporter luciferase construct
(C and E), or HNF4a and PEPCK reporter luciferase construct (D). Luciferase activity wasmeasured 36 hr after transfection. Values represent means6 SEMof at least three
independent experiments performed in quadruplicate; *p < 0.005, versus GAL4-PGC-1a (A), GAL4-VP16 (B), or PGC-1a (C, D, and E).large extent through GCN5 acetyltransferase activity as GCN5m
only slightly repressed PGC-1a -target genes. We next deter-
mined whether changes in gluconeogenic gene expression
reflected increases in hepatic glucose production. Overexpres-
sion of PGC-1a increased glucose secretion by 78%, compared
to control. Expression of GCN5 greatly reduced the ability of
PGC-1a to induce glucose secretion (11% of induction) com-
pared to GCN5m (40% of induction) (Figure 5B). We next tested
whether decreasing endogenous GCN5 levels could affect the
expression of gluconeogenic genes. Adenoviral-mediated ex-
pression of GCN5 RNAi in hepatic cells decreased both mRNA
and protein levels (Figure S4). As expected, knock down of
GCN5 increased PGC-1a’s ability to induce gluconeogenic
genes PEPCK and G6Pase (Figure 5C), correlating with an
elevated induction of glucoseproduction byPGC-1a (Figure 5D).
Taken together, these results indicate that GCN5, through its
acetyltransferase activity, is sufficient to repress PGC-1a func-
tion on endogenous genes and to abolish glucose secretion in
hepatic cultured cells.
GCN5 acetyltransferase controls blood glucose levels
and gluconeogenic gene expression in the mouse
liver during fasting
Finally, to determine whether the PGC-1a/GCN5 pathway was
also operative in live animals, we delivered adenovirus encoding
GCN5via tail injection to themouse liver. As shown in FigureS5A,
hepaticGCN5mRNA levelsweremoderately elevated compared
to endogenous GCN5 mRNA levels. As expected from previous
experiments (Rodgers et al., 2005), ectopic expression of
GCN5 led to an increase in endogenous PGC-1a acetylation
levels (Figure S5B).To determine if GCN5 expression affected
gluconeogenic gene expression, we analyzed mRNA levels of
G6Pase and PEPCK (Figure 6A). Although in the fed state,CELL METABOLISM : JUNE 2006expression of both genes was not significantly changed, GCN5
partially blocked the induction of PEPCKandG6Pase expression
after a 16 hr fasting period. Correlative with these effects on glu-
coneogenic gene expression, fasted blood glucose levels were
reduced in mice expressing GCN5 (Figure 6B). We next analyze
whether this decrease in blood glucose levels was due to a lower
gluconeogenic activity using a pyruvate tolerance test. As seen in
Figure 6C, blood glucose levels were consistently lower in GCN5
expressing mice at different time points following pyruvate
administration, indicating that hepatic conversion of pyruvate
into glucose was partially inhibited by GCN5 expression. Taken
together, these results show that changes of GCN5 levels in he-
patocytes are sufficient to control glucose homeostasis in mice.
Discussion
A precise regulation of the genes that control glucose produc-
tion is required to maintain blood glucose levels in food depriva-
tion states. This control is markedly dysregulated in both type
I and II diabetes and leads to persistent hyperglycemia. In this
complex hormonal and nutrient regulation, PGC-1a is controlled
and recruited to regulate gene expression of key hepatic gluco-
neogenic enzymes (Puigserver et al., 2003; Rhee et al., 2003). In
this molecular context and using a biochemical approach based
on the purification of PGC-1a endogenous protein complexes,
we have identified GCN5 acetyltransferase as a component of
the PGC-1a transcriptional pathway that negatively regulates
expression of gluconeogenic genes through direct acetylation
and nuclear localization of PGC-1a.
The experimental data presented here show the endogenous
protein componentsof thePGC-1acomplex.Notably, twodiffer-
ent protein complexes have been identified with PGC-1a, the
GCN5 and the TIP60 protein complexes, with their respective433
A R T I C L EFigure 4. Nuclear redistribution of PGC-1a by GCN5 acetyltransferase activity
A)Decreased PGC-1aPEPCK andG6Pase promoters occupancy byGCN5. Fao cells were infectedwith the indicated adenovirus and chromatin immunoprecipitation was
performed. Immunoprecipitates were analyzed by the presence of the PEPCK and G6Pase promoter by RT-PCR. Values represent means 6 SEM of two independent
experiments performed in duplicate; *p < 0.05, versus PGC-1a.
B) Localization of PGC-1a to nuclear foci by GCN5. Fao cells were infectedwith adenoviruses expressing FH- PGC-1a or GCN5 (top panel), FH- PGC-1a andGCN5 (middle
panel), or FH- PGC-1a andGCN5m (bottom panel). Immunofluorescencewas performed using amouse anti-HA antibody (shown in green) and a rabbit anti-GCN5 antibody
(shown in red).
C)PGC-1aC-terminal domain is necessary for its nuclear foci localization. HEK293 cells were transfected with HA-PGC-1a and GCN5 (top panel) or HA-PGC-1a (1-570 aa)
and GCN5 (bottom panel). Immunofluorescence was performed as in (B).
D)Colocalization of PGC-1a and RIP140 in nuclear foci. HEK293 cells were transfected with GFP-PGC-1a andHA-RIP140with (bottom panel) or without (top panel) GCN5.
Immunofluorescence was performed using an anti-HA antibody (shown in red).subunits. Of importance, the GCN5 acetyltransferase complex
associated with PGC-1a provides a mechanistic basis by which
acetylation of PGC-1a represses expression of gluconeogenic
genes. Specifically, it clearly delineates a mechanism by which
metabolic gene expression is regulated through intranuclear
localization of a particular transcriptional coactivator. It is con-
ceivable that control of gene expression by localizing key meta-
bolic regulators such as PGC-1a to repressive spatial domains
is a mechanism to efficiently modulate gene expression under
different hormonal and nutrient signals. Although the biochemi-
cal identity of these nuclear foci is unknown, it is remarkable
that we have shown that it colocalizes with a transcriptional
repressor of hormone nuclear receptors, RIP140. Interestingly,434RIP140-deficient mice have altered energy metabolism with
increased energy expenditure (Leonardsson et al., 2004). To
what extent repression of PGC-1a by GCN5 requires colocaliza-
tion and/or interaction with RIP140 is unknown. However, it is
clear from our studies that the gluconeogenic promoters are
not present in these repressive structures, suggesting that the
main mission of this new localization and spatial distribution is
to recruit transcriptional activators away from the chromatin.
We have found that most subunits of the TIP60 protein com-
plex are also associated with the PGC-1a complex. Moreover,
we show here that both proteins directly interact, but the role
of TIP60 complex on PGC-1a function is currently under inves-
tigation. The TIP60 complex has been linked to theDNAdamageCELL METABOLISM : JUNE 2006
Regulation of glucose metabolism by GCN5Figure 5. Inhibition of gluconeogenic PGC-1a function through GCN5 acetyltransferase activity
A) Reduction of gluconeogenic and mitochondrial PGC-1a target genes by GCN5. Fao cells were infected with the indicated adenoviruses and total RNA was analyzed by
Northern blot 2 days after infection.
B) Inhibition of hepatic glucose secretion by GCN5. Fao cells were infected as in (A) and incubated with a gluconeogenic medium before measuring glucose secretion.
Values represent means 6 SEM of three independent experiments performed in duplicate; *p < 0.001 versus AdGFP.
C) Increased PGC-1a gluconeogenic function by GCN5 RNAi. Fao cells were infected with the indicated adenovirus and total RNA was analyzed by RT-PCR 3 days after
infection. Values represent means 6 SEM of three independent experiments performed in duplicate; *p < 0.05 and **p < 0.01 versus AdControl RNAi.
D) Increased PGC-1a-induced hepatic glucose secretion by GCN5 RNAi. Fao cells were infected as in (C) and incubated with a gluconeogenic medium before measuring
glucose secretion. Values represent means 6 SEM of two independent experiments performed in triplicate; *p < 0.01 versus AdControl RNAi.and repair response (Ikura et al., 2000; Kusch et al., 2004). Inter-
estingly, PGC-1a has been associated with an increased in ROS
detoxification enzymes (St-Pierre et al., 2003). It could be con-
ceivable that in certain promoters of genes involved in oxidative
stress and DNA repair the TIP60 complex could recruit PGC-1a
to regulate expression of these genes. Another important mech-
anistic question is how theGCN5 and TIP60 complexes comple-
ment the function of two other classes of proteins shown to
interact with PGC-1a, the HATs p300 and SRC-1 (Puigserver
et al., 1999) as well as the TRAP/mediator complex (Wallberg
et al., 2003). As it relates to GCN5 as a negative regulator of
PGC-1a, a possibility is a different spatial localization that pre-
cludes activation with these other set of proteins. Interestingly,
TIP60 complex contains RuvBL1 and RuvBL2, two proteins
with DNA helicase enzymatic activity that could cooperate
with p300 and TRAP complex to remodel chromatin and modu-
late gene expression. Further studies will address the interplay
between these different set of proteins to regulate PGC-1a
transcriptional activity.
In a food deprivation physiological response, SIRT1 deacety-
lase regulates the function of PGC-1a on gluconeogenic genes
and hepatic glucose production (Rodgers et al., 2005). The
results presented here indicate that there exists an oppositeCELL METABOLISM : JUNE 2006mechanism throughGCN5 acetylation of PGC-1a. This provides
strong evidence that the acetylation status of PGC-1a is critical
to the transcriptional function of this coactivator. We show
here that modulating the activity of GCN5 in hepatic cells and
in the mouse liver results in altered expression of gluconeogenic
genes, glucose production and blood glucose levels, indicating
that this pathway is operative in mice. Whether GCN5 is directly
regulated in response to hormonal and/or nutrient signals to con-
trol the biological function of PGC-1a in key metabolic tissues is
currently under investigation. Alternatively, it is conceivable that
GCN5 might be constitutively active and the ‘‘true’’ metabolic
regulatory sensor modulating acetylation of PGC-1a is SIRT1.
As SIRT1 has been implicated in biological processes affecting
life span in different organisms (Bitterman et al., 2003; Bordone
andGuarente, 2005; Rogina andHelfand, 2004), it could be pos-
sible that certain activities of SIRT1 are antagonized byGCN5. At
least, what we show here is that the metabolic gluconeogenic
pathway that is activated by caloric restriction and SIRT1 (Rodg-
ers et al., 2005) is oppositely regulated by GCN5, whether the
same antagonism is applied to other SIRT1 pathways such as
resistance to oxidative stress is an attractive hypothesis.
Finally, it is important to note that GCN5 acetyltransferase en-
zymatic activity may provide a target for therapeutic drugs to435
A R T I C L EFigure 6. Inhibition of gluconeogenic gene expres-
sion by GCN5 acetyltransferase activity in the
mouse liver
A) Inhibition of gluconeogenic gene induction during
fasting by GCN5. Total RNA was isolated from mice
injected with either GFP or GCN5 adenoviruses.
mRNA levels for PEPCK and G6Pase were analyzed
by RT-PCR in fed and fasted states. Values represent
means6 SEM, with nR 6 from two independent ex-
periments; *p < 0.01 and **p < 0.005, versus AdGFP.
B) Decreased blood glucose levels during fasting
by GCN5. Blood glucose levels were measured in
the fed or fasted states from mice injected with
either GFP or GCN5 adenovirus. Values represent
means 6 SEM with n R 13 from three independent
experiments; *p < 0.05, versus AdGFP.
C) GCN5 decreases glucose production from pyru-
vate. Pyruvate was injected intraperitoneally at
a dose of 2 g/Kg into fasted mice expressing either
GFP or GCN5. Blood glucose levels were monitored
after pyruvate injection. Values represent means 6
SEM with n = 7 from two independent experiments;
*p < 0.01 and **p < 0.005 versus AdGFP.treat glucose metabolic disorders in diabetes or aging, by po-
tentially modulating the function of PGC-1a in tissues such as
the liver to control glucose production.
Experimental Procedures
Constructs
The catalytically inactive acetyltransferase mutant GCN5 (Y621A/P622A)
(GCN5m) was generated by site-directed mutagenesis and verified by DNA
sequencing. Target sequence of the RNAi directed against GCN5 was
tgttcgagctctcaaagat. Wild-type and GCN5m, Flag-HA-PGC-1a (FH-PGC-1a)
and GCN5 RNAi adenovirus were constructed using the pAd-Easy system.
Basically, inserts were cloned into the pAdTrack shuttle vector and adenovi-
rus constructs were created by recombination of the shuttle vector and
pAdEasy vector by electroporation into BJ5183-AD-1 bacteria (Stratagene).
Plasmids maps and sequences of constructs used in this study are available
upon request.
Cell culture and treatments
HEK293 cells were maintained in DMEM with 10% fetal bovine serum (FBS).
Fao rat hepatocytes were cultured in Ham’s F-12 Coon’s modified media
(Biosources) with 5% FBS. Fao cells were infected with adenoviruses for 3
hr and incubated in the same media for an additional 24 hr. Cells were then
washed with PBS and incubated with RPMI with 0.5% BSA for 16 hr before
harvesting.
Protein complex purification
PGC-1a complexes were purified from approximately 40 mg of nuclear
extracts prepared from Fao cells infected with adenoviruses expressing
PGC-1a protein fused with N-terminal Flag- and HA-epitope tags
(FH-PGC-1a). As a control, we performed mock purification from Fao cells
infected with adenoviruses expressing GFP. Nuclear extracts were obtained
as previously described (Dignam et al., 1983) and dialyzed against a buffer
containing 20 mM Tris-HCl (pH 8), 100 mM KCl, 0.2 mM EDTA, 0.1%
Tween-20, 10% glycerol, 20 mM b-mercaptoethanol, and 0.1 mM PMSF.
Protein complex purification was performed as described in (Nakatani and
Ogryzko, 2003) with several modifications. Basically, nuclear extracts were
separated through a Sephacryl S-300 size exclusion column (AmershamBio-
sciences) and fractions containing FH-PGC-1a were collected. Protein
complexes were further purified by immunoaffinity chromatography with
Flag M2 antibody linked to agarose beads (Sigma). Protein complexes436were then eluted by incubating with Flag peptide (0.2 mg/ml) and the eluted
material was separated in a 4%–20% acrylamide gradient gel. Protein bands
were excised from SDS-PAGE gels, digested with trypsin, and analyzed by
liquid chromatography-tandem mass spectrometry (LC-MS/MS) as de-
scribed previously (Ibarrola et al., 2003). The mass spectra were acquired
on a Micromass-Waters Q-TOF API-US mass spectrometer (Manchester,
UK). In order to identify the proteins, mass spectrometric data were searched
against NCBI non-redundant database by using Mascot version 1.9. For
density gradient sedimentation, 0.2 ml of purified material was loaded onto
a 4 ml glycerol gradient (15%–40%) and centrifuged at 55.000 rpm in
a Beckman SW55Ti rotor for 2.5 hr. Fractions were collected from the top
and proteins were detected by Western blot using the indicated antibodies.
Protein interaction analysis
Protein-protein interaction analysis were performed by either coimmunopre-
cipitation or in vitro binding assays. For coimmunoprecipitation experiments,
Fao cells were infected with adenoviruses expressing FH-PGC-1a or GFP
and nuclear extracts were obtained as described in (Dignam et al., 1983).
Immunoprecipitation was performed by incubating with M2 Flag antibody
and eluting with Flag peptide. The eluted material was then analyzed by
Western blot using the indicated antibodies. Antibodies used in this study
are anti-GCN5 (Biolegends), anti-TAFII31 (provided by Robert G. Roeder),
anti-SAP130 (Santa Cruz), anti-PAF65b (provided by Yoshihiro Nakatani),
anti-RuvBL1 (provided by Anyndia Dutta), and anti-KAP-1 (provided by Frank
J. Rauscher). For in vitro binding assays, GST–PGC-1a and GST–GCN5 frag-
ments were expressed in bacteria (BL21) by isopropyl thiogalactoside
induction for 3 hr at 30ºC and purified on sepharose beads containing gluta-
thione. [35S]-labeled proteins were made with a TNT reticulocyte lysate kit
(Promega). Equal amounts of GST fusion proteins (1 mg) were mixed with 5 ml
of the in vitro translated proteins in a binding buffer containing 20mMHEPES
buffer (pH 7.7), 75 mM KCl, 0.1 mM EDTA, 2.5 mM MgCl2, 0.05% NP40,
2 mM dithiothreitol, and 10% glycerol. After 1 hr of in vitro binding reaction,
agarose beads were washed three times with the binding buffer. Bound
proteins were separated by SDS-PAGE and analyzed by autoradiography.
Analysis of protein acetylation
Flag-tagged proteins were expressed in 293 cells using PolyFect (Qiagen) or
in Fao cells by adenoviral infection. Whole-cell extracts were obtained 36 hr
after transfection or infection and subjected to immunoprecipitation with
anti-Flag M2 antibody linked to agarose beads. For in vivo acetylation anal-
ysis, PGC-1a was immunoprecipitated with anti-PGC-1a antibody (H-300,
Santa Cruz) from nuclear extracts obtained from fasted livers of mice injectedCELL METABOLISM : JUNE 2006
Regulation of glucose metabolism by GCN5with either GFP or GCN5 adenovirus. The immunoprecipitates were then
separated by SDS-PAGE and immunoblotted using the acetyl-Lysine anti-
body (Cell Signaling and Technology) and the M2 Flag antibody (Sigma) or
anti-PGC-1a H300 antibody to detect lysine acetylation and total protein
levels, respectively.
In vitro protein acetyltransferase assay
Histone acetyltransferase assayswere performed using 5 mg of core histones
(Upstate) and 5 ml of the PGC-1a-purified or the mock-purified material in
acetylation buffer (50 mM Tris-HCl [pH 8], 10% glycerol, 40 mM sodium bu-
tyrate, 20 mM nicotinamide, 4 mM DTT, and 1 mM PMSF) with 1 nmol [14C]-
acetyl-CoA (55mCi/mmol). After incubation at 30ºC for 10min, histoneswere
separated in 15% SDS-PAGE and analyzed by autoradiography. Same pro-
tocol was used to analyze PGC-1a acetylation but using 1 mg of recombinant
GST-PGC-1a (1–400 aa) and 1 mg of recombinant GST-GCN5 (352–837 aa)
and incubating at 30ºC for 1 hr. After extensive washing, incorporated radio-
activity was measured by liquid scintillation counting.
Transcriptional activation assays
HEK293 cells were transiently transfected in 24-well dishes using PolyFect
(Quiagen) with the indicated plasmids. The ratio DNA:PolyFect was 1:2. Cells
were lysed 36 hr after transfection and luciferase assays were performed.
Gene expression analysis
Gene expressionwas analyzed either byNorthern blot or real-timePCR. Total
RNA prepared from Fao cells or mouse livers was extracted with Trizol
(Invitrogen). RNA messages were analyzed by Northern blot using specific
32P-labeled probes. Alternatively, complementary DNA generated by Super-
script II enzyme (Invitrogen) was analyzed by quantitative reverse-transcrip-
tase-mediated PCR (Q-RT2PCR) using an iQ SYBR Green Supermix
(Bio-Rad). All datawere normalized to tubulin expression. Theoligonucleotide
primers used are provided as Supplemental Data (Figure S6).
Hepatic glucose output
Fao cells were grown in 6 well dishes and infected with the indicated adeno-
virus. Two or three days after infection, culture medium was replaced with 1
ml of glucose-free RPMI supplemented with 0.5% BSA, 20 mM sodium lac-
tate and 2mM sodium pyruvate. After 4 hr incubation, glucose concentration
in the culture medium was measured using the glucose-6-phosphate dehy-
drogenasemethod (Williamson et al., 1967). Glucose values were normalized
to the total protein content and expressed as fold increase versus control
(AdGFP or AdControl RNAi) cells.
Chromatin immunoprecipitation analysis
Fao cells were infected with the indicated adenovirus. Cells were cross-
linked with 1% formaldehyde at 37ºC for 10 min and sonicated in lysis buffer
containing 50 mM Tris-HCl (pH 8.1), 10 mM EDTA, 1% SDS and protease in-
hibitors. Supernatants were incubatedwith the anti-HA antibody (clone 3F10)
linked to agarose beads (Roche) at 4ºC for 16 hr. After extensive washing im-
munoprecipitants were eluted with 2%SDS in 0.1MNaH2CO3. Cross-linking
was reversed by heating at 65ºC for 4 hr and eluates were treated with pro-
teinase K (Roche) at 45ºC for 1 hr. DNA was analyzed by Real-Time PCR us-
ing an iQ SYBR Green Supermix (Bio-Rad). Forward and reverse primers
used were 50 tggcctggcttcgaggaccagg 30 and 50 aacctagccctgatctttggactc
30, for G6Pase promoter, and 50 gtgggagtgacacctcacagc 30 and 50 aggacagg
gctggccgggacg 30 for PEPCK promoter. Values were normalized to the
amount of G6Pase and PEPCK promoters in the input.
Immunofluorescence microscopy
Immunofluorescence was performed 36 hr after transfection or infection with
the indicated antibodies. Cells were fixed by incubating in 4% paraformalde-
hyde for 10 min at room temperature and permeabilized by incubating with
0.2% Triton X-100 in PBS for 10 min. Cells were then blocked by incubating
with 3% BSA in PBS for 30 min and treated with the indicated primary anti-
body for 1 hr. Primary antibodies used in this study aremouse HA.11 (Babco),
rabbit anti-GCN5 (Biolegends), mouse anti-Sm (provided by Michael J. Ma-
tunis), mouse anti-SC35, mouse anti-U2-B0 0 (provided by David L. Spector)
and human anti-U1snRNP70K (provided by Antony Rosen). After four
washes with 0.1% NP-40 in PBS, cells were incubated with anti-human
TR-conjugated, anti-rabbit Cy3-conjugated or anti-mouse Cy5-conjugatedCELL METABOLISM : JUNE 2006secondary antibodies (Jackson Immunoresearch) for 1 hr. After being
washed with PBS 0.1% NP-40 four times, cells were examined using a fluo-
rescence microscope (Carl Zeiss Axiovert 135) and IPLab software (Scana-
lytics) was used to collect digital images.
Animal experiments
Male, 8-week-old BALB/c mice were purchased from Harlan Laboratories.
Recombinant adenovirus (5 3 109 pfu) was delivered by tail-vein injection
to mice. Fed and 16 hr fasting blood glucose levels were measured from
tail-vein blood 4 days after injection, using the Ascensia ELITE XL Blood
Glucose Monitoring System (Bayer). Animals were sacrficed and the livers
were removed and snap-frozen. Where indicated, pyruvate was adminis-
tered intraperitoneally to fasted mice at a dose of 2 g/Kg.
Statistical analysis
Results are given as means 6 SEM Statistical analyses were performed
using the unpaired two-tailed Student’s t test, and the null hypothesis was
rejected at the 0.05 level.
Supplemental data
Supplemental data include six figures and can be found with this article
online at http://www.cellmetabolism.org/cgi/content/full/3/6/429/DC1/.
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